This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Dietary Restrictions and Drug Interactions With Monoamine Oxidase Inhibitors: The State of the Art

Mark Hyman Rapaport, MD

Published: July 16, 2007

Article Abstract

Antidepressant activity of monoamine oxidase inhibitors (MAOIs) was initially noted in the 1950s, andby the early 1960s, they were a mainstay of antidepressant treatment. Reports of adverse events such as acutehypertensive reactions following the ingestion of certain foods and beverages tempered clinicians’ enthusiasmfor MAOIs. Introduction of the tricyclic antidepressants and the selective serotonin reuptake inhibitorsled to declines in the use of MAOIs. However, MAOIs have been well established as an effective interventionfor people with treatment-resistant depression, and transdermal formulations may provide a valuabletherapeutic option and eliminate the drug-food interaction.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 68

Quick Links: